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Chapter 1. Introduction
1.1 Prostate Cancer
Prostate cancer (PCa) is the most common male malignancy and the second
leading cause of cancer-related death in men in the U.S. The risks of getting PCa are
related to ancestry, increasing age as well as the environment and lifestyle, e.g., the
incidence of PCa in African Americans is twice higher than White Americans and is 1520-fold higher than native Asian, and the risk among immigrant Asian is significantly
higher than native Asian [1]. Besides, Family history of PCa is the only definite risk
factor for prostate cancer. First-degree relatives of men with prostate cancer have about
twice higher risk of disease compared to men in the general population [2].
Prostate-specific antigen (PSA), also known as kallikrein-3 (KLK3), is a
glycoprotein enzyme encoded in humans by the KLK3 gene. The blood PSA level in men
with prostate cancer is usually increased and the PSA test was approved by the FDA for
monitoring the progression of PCa in men who had already been diagnosed with the
disease. PSA test, as a method for PCa screening, are able to detect the disease at an early
stage. However, the clinical benefits of this screening are uncertain: the elevated PSA
level doesn’t necessarily mean cancer, benign prostatic hyperplasia (BPH), or an enlarged
prostate since prostatitis can also raise PSA levels. Studies indicate that about 70% to 80%
of men with an elevated PSA do not have cancer as determined by biopsy, and 40% to 56%
will be affected by over-diagnosis leading to invasive treatment, while about 20% of men
who have cancer have a normal PSA level [3, 4]. Besides, the value of PSA screening in
preventing cancer-related death is also contradictory. Randomized Prostate-Cancer

2
Screening Trials showed no significant benefit on decreasing death rate in the U.S.[5],
but did show a 20% decrease of death rate in PCa patients in Europe [6].
Since the first demonstration in 1941 by Huggins and Hodges that androgen
manipulation in patients with advanced PCa has great influence on the progression of the
disease [7], androgen deprivation therapy (ADT) has been a standard treatment for men
with advanced PCa. ADT can be achieved by either surgical castration which removes
testicles or by chemical castration which uses luteinizing hormone-releasing hormone
(LHRH) agonists or antagonists to block the production of testicular testosterone via
negative feedback or competitive inhibition, respectively [8]. Despite the initial
effectiveness of ADT, PCa cells could develop mechanisms of resistance leading to
castration-resistant PCa (CRPC) within 2-3 years of ADT [9]. Androgen receptor (AR)
signaling is a driving force of PCa at all stage, including CRPC. Mechanisms to reactivate AR signaling under ADT include: 1) AR gene amplification [10, 11] or AR
protein overexpression [12] to respond to low levels of androgen; 2) AR mutations
(promiscuous pathway) which broaden the specificity of AR so it can be activated by
molecules such as corticosteroids or clinically-used AR antagonists other than androgen
[13, 14]. For example, T877S/H874Y and W741C/W741L mutations convert flutamide
and bicalutamide (Figure 1) to AR agonists, respectively [15, 16]; 3) Alternative
androgen production by increasing intratumoral androgen levels via de novo androgen
synthesis. [17, 18]. FDA-approved abiraterone blocks androgen biosynthesis within testes,
adrenal gland and prostate via inhibiting cytochrome P450 17A and shows clinical
benefits in CRPC patients [19]; 4) Expression of AR splice variants (AR-Vs) without
ligand binding domain (LBD) also contributes to the development of CRPC [20, 21]: AR-
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Figure 1. AR antagonists in clinical use or in clinical development.

Vs are constitutively active and their biological functions cannot be inhibited by
conventional AR antagonists targeting LBD or by abiraterone targeting androgen
biosynthesis; 5) Activation of AR in a ligand-independent manner (outlaw pathway) is
also an important mechanism of resistance: examples includes growth-factor-activated
outlaw pathways [22], receptor-tyrosine-kinase-activated outlaw pathways [23, 24] and
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Figure 2. The chemical structures of dietary and synthetic isothiocyanate derivatives.

the activation of Akt pathway [25]; 6) CRPC can also be promoted by activation of
compensatory signaling pathways which bypass AR axis, e.g. PI3K/AKT and AR
signaling pathways cross-regulate each other by reciprocal feedback which means downregulation of one pathway will activate the other [26]. Simultaneous inhibition of both
pathways synergistically inhibited cancer progression [27] and delayed the emergence of
resistance [28]. Because AR is the most therapeutically-relevant drug target in PCa
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treatment, new AR antagonists, such as enzalutamide [29] , ARN-509 [30] and galeterone
[31] (Figure 1) have been developed to block AR signaling pathway in CRPC patients.
1.2 Enzalutamide
Enzalutamide (Enz, Figure 1) is a potent AR antagonist and was approved for the
treatment of metastatic CRPC. It has higher AR binding affinity (5-8 fold, [32])
compared to last-generation AR antagonists, such as bicalutamide, and doesn’t induce
AR nuclear translocation. Enz has multiple inhibitory functions on the AR axis: it
competes androgen for AR binding, inhibits androgen-stimulated AR nucleus
translocation, and inhibits liganded AR binding to DNA on the androgen response
elements (ARE). Its approval was based on two successful Phase 3 clinical studies.
AFFIRM trial was conducted in patients with metastatic CRPC (mCRPC) who have gone
through docetaxel chemotherapy. The results indicated that Enz prolongs the median
overall survival for 4.8 months compared with placebo group [33], which led to its
approved by FDA in 2012 for the treatment of mCRPC after chemotherapy. Another
phase 3 trial known as PREVAIL trial was focused on chemotherapy naïve mCRPC
patients. Enz significantly reduced the risk of radiographic progression and significantly
improved overall survival [34]. FDA further approved enzalutamide for this patient
population [35]. However, acquired resistance to enzalutamide emerges after short period
of treatment and patient survival benefit is short-lived. The mechanisms leading to
enzalutamide resistance include AR mutations (e.g., F876L mutation converted
enzalutamide into an AR agonist [36]), up-regulation of AR splice variants,
glucocorticoid receptor overexpression, intracrine synthesis of androgens, crosstalk with
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growth factor, neuroendocrine transformation, neuroendocrine transformation, and
immune evasion [37].
1.3 Dietary Isothiocyanates
Isothiocyanates (ITCs) (Figure 2) are active metabolites of glucosinolates from
cruciferous vegetables (e.g. broccoli, cabbage, watercress). Epidemiological studies
suggest a correlation between high intake of cruciferous vegetables and low incidence of
PCa [38, 39]. ITCs have been demonstrated as one of the major dietary components
contributing to this benefit.
Sulforaphane (SFN) is one of the ITCs that has both chemopreventive and
therapeutic activities against PCa [40]. It is generated from the myroinase-catalyzed
hydrolysis of glucoraphanin [41] (Figurer 3). Epithiospecifier protein (ESP), a protein
also presented in broccoli, leads to the formation of SFN nitrile which has no
anticarcinogenic activity [42]. Gentle heating decreases ESP activity and could increase
SFN formation while excessive heating denatures myroinase, thus decreases conversion
of glucoraphanin to SFN (Figure 3) [43]
After intake into the body, SFN is metabolized through the mercapturic acid
pathway. SFN first conjugates with GSH by glutathione S-transferases (GSTs). Then
with the help of γ-glutamyl-transpeptidase (GTP) and cysteinyl-glycinease (GCase),
glutamic acid and glycine residues of GSH are removed to form SFN-Cys conjugate.
Finally, N-acetyltransferase (NAT) acetylates cysteine conjugate to form SFN-NAC
which is then getting into systemic circulation via active transportation and is excreted in
urine (Figure 4).
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The epidemiological relationship between cruciferous vegetables and PCa
triggered extensive studies to illustrate the mechanisms behind the anti-prostate cancer
activity of SFN and other ITCs, such as PEITC, BITC, etc. [44]. A phase 2 clinical study
testing SFN-rich broccoli sprout extracts in men with recurrent prostate cancer was
completed recently [45], although the treatment regimen (200 μmoles/day of SFN-rich
extracts, up to 20 weeks) did not lead to ≥50% PSA declines in the majority of patients,
the on-treatment PSA doubling time was significantly lengthened (9.6 months vs. 6.1
months) without Grade 3 adverse events, indicating a promising safety profile and a
potential for further dose escalation. The biological effects and potential molecular
targets of SFN (or other ITCs) in prostate cancer cells are briefly reviewed as follows.

Figure 3. Mechanism for the formation of sulforaphane and sulforaphane nitrile in
broccoli florets and sprouts. Myrosinase catalyzes transformation of glucosinolate to
SFN.
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1.3.1. Observed Anticancer Effects of SFN
Induction of cell cycle arrest
SFN (20 µM) induced S phase arrest due to down-regulation of cyclin D1, cyclin
E, Cdk4, and Cdk6 proteins in LNCaP cell [46]. SFN also induced G2/M arrest by
activation of Chk2-mediated phosphorylation of Cdc25C in PC-3 or JNK-mediated
signaling in DU145 cells [47, 48].
Induction of apoptosis
SFN-induced apoptosis in PC-3 cell was associated with up-regulation of Bax,

Figure 4. Mecaputuric acid pathway. SFN is metalized by various enzymes to
become SFN-NAC conjugate.
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down-regulation of Bcl-2 and activation of caspases-3, -9 and -8 [49]. SFN treatment
results in decreased protein levels for inhibitor of apoptosis (IAP) family members
(cIAP1, cIAP2 and XIAP) and nuclear factor κB (NFκB) in PC-3 cells, and increased
protein levels for Apaf-1 in both PC-3 and LNCaP cells [50]. Survivin which is an
inhibitor of apoptosis and a mitosis regulator is down-regulated by SFN in PC-3 cells
[51].
Inhibition of migration and metastasis
Epithelial-mesenchymal transition (EMT) is a biological process by which
epithelial cells are polarized to gain enhanced ability of migration, invasion, resistance to
apoptosis and production of microenvironment extracellular matrices (ECMs)
components to become mesenchymal cell phenotype [52]. EMT is involved in the cancer
progression and is responsible for the metastasis of cancer, including PCa[53]. Ecadherin as a tumor suppressor is critical for the formation and maintenance of adherent
junctions between epithelial cells. Loss of E-cadherin expression is an important factor
leads to EMT-associated invasion and metastasis [54]. In cancer cells, overexpression of
onco-protein ERG causes up-regulation of its downstream target chemokine receptor type
4 gene (CXCR4) which is positively correlated with the cell motility [55]. CXCR4 has
recently been identified as a novel target of SFN in PCa cells: treatment of LNCaP,
22Rv1, C4-2 and PC-3 cells with SFN (5 µM, 12 h) resulted in down-regulation of
CXCR4 and inhibition of cell migration [56]. Labsch et al. demonstrated that SFN,
particularly in combination with TNF-related apoptosis-inducing ligand (TRAIL),
reduces the levels of proteins required for EMT and cell migration in PC-3 and DU145
cells [57]. A recent study also indicated that SFN inhibits invasion of PCa (DU145 cells)
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by activating ERK1/2 to up-regulate E-cadherin and down-regulate CD44v6, which
further leads to reduced matrix metalloproteinase-2 (MMP-2) expression and activity [58].
Inhibition of cancer stem cells
Cancer stem cells (CSCs) refers to a subset of tumor cells that possess
characteristics of normal stem cells but are responsible for tumor initiation, metastasis,
resistance and relapse due to self-renewal, multi-lineage differentiation and resistance to
chemotherapy and radiation therapy [59-61]. SFN was reported to inhibit breast CSCs
both in vitro and in vivo [60]. The aldehyde dehydrogenase (ALDH)–positive breast
CSCs was decreased by SFN via daily injection (50 mg/kg, 2 weeks) in a mouse model.
The inhibition of breast CSCs by SFN is potentially due to down-regulation of the Wnt/βcatenin self-renewal pathway [60]. Kallifatidis et al. indicated that SFN increases druginduced toxicity toward CSCs in both prostate and pancreatic cancer. In vivo, the
combination of SFN and gemcitabine completely abolished growth of pancreatic CSC
xenografts and tumor-initiating potential without induction of additional toxicity [59].
SFN was reported to inhibit prostate CSC properties, e.g., inhibiting the expression of
Nanog, SOX2, CXCR4, Jagged1 and notch 1; it also disrupts TRAIL-caused NF-κB
binding; a combination of SFN and TRAIL effectively suppressed tumor engraftment
and tumor growth without obvious adverse effects in vivo [57].
1.3.2. Cellular Targets of ITCs
The pleiotropic anticancer effects of SFN and other dietary ITCs are derived from
their interactions with various cellular targets. The ITC functionality, which is a
biological-tolerable electrophile in certain dosage range, is capable of conjugating with
cellular glutathione (GSH), protein thiols and other nucleophilic amino acid residues.
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These fundamental chemical properties determine the interactions of ITCs with their
cellular targets , leading to the aforementioned cellular effects [62]. In the following
section, we focus on the influence of SFN on histone deacetylase (HDAC) and heat shock
protein 90 (Hsp90). Both HDAC inhibition and Hsp90 disruption are effective ways to
antagonize AR functions in PCa cells.
Inhibition of HDACs
HDAC are a class of enzymes that remove the acetyl group from lysine residues
of histones or non-histone proteins. HDACs can be classified into four classes: class I
(HDAC1, HDAC2, HDAC3, and HDAC8), class II (HDAC4, HDAC5, HDAC7, and
HDAC9 in the IIa subclass, and HDAC6 and HDAC10 in the IIb subclass), class III
(Sirt1 to Sirt7), and class IV (HDAC11) [63]. Class I, II and IV are zinc dependent
enzymes. HDACs are abundantly expressed in prostate cancer [64] and play important
roles in the regulation of the AR [65]. HDAC1 is up-regulated in both androgen sensitive
and hormone refractory prostate cancer cells, leading to significant enhancement of cell
proliferation [66]. It has also been reported that HDAC2, HDAC3 and HDAC8 are
overexpressed in cancer tissues compared to normal epithelium [67]. Up-regulated SIRT1
expression was found in androgen-refractory PC-3 and DU145 cells compared to
androgen-sensitive LNCaP cells [68]. HDAC inhibitor (HDACi) LAQ824 were found to
decrease AR protein levels in PCa cells via inhibition of HDAC6, which causes increased
proteasomal degradation of AR [69, 70]. Another HDACi SAHA (Figure 5) inhibits AR
at the transcriptional level to reduce AR mRNA production [71], Consequently, HDACis
have been clinically tested for the treatment of CRPC. Although multiple HDACis have
been approved for the treatment of lymphoma and myeloma, e.g. vorinostat (i.e. SAHA)
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Figure 5. The structures of FDA-approved HDAC inhibitors
and romidepsin for cutaneous T cell lymphoma, belinostat for peripheral T cell
lymphoma and panobinostat for multiple myeloma, all the clinical trials of HDACis for
solid tumors (including prostate cancer) failed due to lack of efficacy and systemic side
effects (e.g., cardiovascular toxicity).
The HDAC inhibition activity of SFN was first reported by Myzak et al.: SFN
dose-dependently (3, 9, 15 µM) increased TOPflash activity which is inversely correlated
with the HDAC activity. Both global and localized histone acetylation were increased by
the treatment of SFN. It was also indicated that the cysteine and N-acetylcysteine
metabolites of SFN had HDAC inhibition activity while SFN itself and glutathione
conjugate didn’t [72]. This work proposed a chemistry foundation of ITC-caused HDAC
inhibition. The similar effect was found in prostate epithelial cell lines BPH-1, LNCaP
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and PC-3, SFN (15µM) decreased HDAC activity in all the three cell lines by 30-40%
with 50-100% increase in acetylated histone [73].
HDACi activity of SFN was also demonstrated in vivo. Significant inhibition of
HDAC activity and increase in acetylated histones H3 and H4 in the colonic mucosa were
observed when mice were treated with a single oral dose of 10 µmol SFN. Long-term
dietary treatment increased acetylated histones and p21WAF1 in multiple tissues including
prostate. Tumor multiplicity in Apcmin mice was also suppressed by SFN with increased
acetylated histones in the promoter regions of the P21 and Bax genes [74]. Besides, daily
consumption of 7.5 μmol per animal of SFN for 21 days suppressed growth of human
PC-3 cells in male nude mice as well as HDAC activity in xenografts, prostate and
mononuclear blood cells (MBC) [75]. A single dose of 68g broccoli sprouts inhibited
HDAC activity in peripheral blood mononuclear cells (PBMC) in human subjects [75].
These works demonstrated bioavailability and tissue accumulation of SFN in
experimental animal models and in human subjects.
HDAC6 is a zinc-dependent, class-IIb HDAC enzyme and locates in cytoplasm
due to the presence of nuclear export signals (NES) and serine-glutamine-containing
tetradecapeptide modules [76]. A portion of HDAC6 physically associates with Hsp90
and functions as an Hsp90 deacetylase [77], and deacetylated Hsp90 can chaperone and
stabilize its client proteins [78]. The mechanism of SFN to antagonize AR was proposed
by Gibbs et al. Their study found that SFN (10-20µM) can inhibit HDAC6 enzymatic
activity, reduce HDAC6 protein levels and cause hyperacetylation of Hsp90, leading to
dissociation of AR from Hsp90. The dissociated AR was subjected for proteasomal
degradation [79] (Figure 6).
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Direct interactions between SFN and Hsp90
In addition to inhibiting HDAC6 and causing Hsp90 hyperacetylation, direct
interactions between SFN with Hsp90 were also reported. As electrophilic compounds,
ITCs (including SFN) may covalently modify Hsp90 on surface-exposed nucleophilic
amino acid residues and disrupt its biological functions. By using nuclear magnetic
resonance spectroscopy and LC-MS peptide mapping methods, SFN (around 15µM) was
found to be covalently attached to the N-terminal domain of Hsp90 and this modification
attenuated the interaction of Hsp90 with a co-chaperone Cdc37, which promoted the
proteasomal degradation of Hsp90 client proteins such as Akt and Cdk4, resulting in cell
death in a pancreatic cancer model [80]. In another study, an SFN analogue 6-HITC
(25µM) was incubated with human recombinant Hsp90β. Proteomics analysis showed
that 6-HITC formed covalent adduct with Cys-521 amino acid residual of Hsp90.
Interestingly, through a transthiocarbamoylation mechanism, even conjugation with a

Figure 6. SFN attenuate AR signaling via HDAC6 inhibition.
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small molecule thiol cannot abrogate the capability of 6-HITC to modify cysteine
residues of cellular proteins [81]. SFN mimetic, sulphoxythiocarbamates, were also found
to form cysteine adducts with recombinant Hsp90β, which caused degradation of client
proteins in MCF-7 cell (RAF1, HER2, CDK1, CHK1, etc.) and inhibited MDA-MB-231
breast cancer cell proliferation [82]. These results suggest that electrophilic compounds,
such as ITC, can be used to target the cysteine residues or other nucleophilic amino acid
residues of Hsp90, drug-protein adducts formation would lead to degradation of client
proteins and growth inhibition of cancer cell.
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Chapter 2． Rationale and Experimental Design
2.1. Rationale
Androgen receptor (AR), especially mutated full length AR and truncated AR-Vs,
are major driving forces of CRPC. An agent that can effectively compete androgen
binding, meanwhile down-regulating AR/AR-Vs and AR compensatory pathways will
certainly advance CRPC treatment. In addition to inducing the degradation of full length
AR, recent study also suggested that disrupting Hsp90 could down-regulate AR-Vs:
although AR-Vs are not Hsp90 client proteins, the mRNA splicing process could be

Figure 7. The structures of proposed Enz-ITC hybrids.
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negatively influenced by heat shock response, a typical cellular adaption to Hsp90
inhibition [83]. Considering the biological connections of AR and Hsp90 as well as the
pharmacological properties of enzalutamide (Enz) and dietary ITCs, we have designed a
class of Enz-SFN hybrid compound (Figure 7) to target AR-Hsp90-HDAC6 complex as
a way to achieve aforementioned therapeutic goals, i.e. antagonizing AR function and
simultaneously down-regulating compensatory onco-proteins, such as Akt which are also
chaperoned by Hsp90.
We hypothesized that an Enz-like, high affinity AR ligand could be used as
vehicle to concentrate ITC components to AR-overexpressing CRPC tumors and then
intracellularly deliver ITC to AR-Hsp90-HDAC6 complex. The locally concentrated ITC
could more efficiently disrupt Hsp90 by either inhibiting a pool of AR-associated
HDAC6 or by covalently modifying Hsp90, which further triggers Hsp90 dysfunction
and degradation of AR and other oncogenic client proteins, such as HDAC6 and Akt
(Figure 8). The goal of this thesis is to establish an efficient synthetic route toward AR

Figure 8. Proposed mechanism of AR-directed HDAC6/Hsp90 inhibition by EnzITCs.
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Figure 9. The chemical structures of synthetic targets.
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ligand (Enz)-ITC hybrids and preliminarily investigate their effects on the growth and the
function of AR, such as transcriptional activity and expression levels in representative
prostate cancer cell lines.
2.2. Experimental Design
2.2.1. Chemistry
Previous SAR [84] and our molecular docking of Enz to AR suggested that the
trifluoromethyl benzonitrile ring points inside the AR binding cavity in LBD and cyano
group is essential for AR binding by forming hydrogen bonds (H-bonds) with Arg752
and Gln711. Thiohydantoin ring of Enz is in its optimized form from an extensive SAR
study [29] and was kept intact in our molecular design. This conformationally restricted
ring forces the rest of the molecule extend outside the AR pocket and point to a “H11
pocket”, a region near the C terminus of helix 11 and the loop connecting helices 11 and
12 [36]. Based on this predicted AR binding mode, we decided to introduce ITC group on
fluorobenzene ring which points toward the opening of AR binding pocket where enough
space is available to accommodate ITC moiety. We also replaced fluorobenzene ring of
Enz with a pyridine ring, supported by the lowered cLogP values (6.29 of compound 12b
vs 7.93 of compound 30, Figure 9), we hypothesized that this modification would
improve water solubility of Enz-ITC hybrid drug and would not interfere AR binding.
The chemical reactivity of ITC is a critical factor to influence its biological effects.
A general observation is that the chemical reactivity of an arylalkyl ITC is reduced with
increasing the length of carbon chain, in another word, an arylalkyl ITC with a relative
longer chain (up to six methylene units) is more stable and may achieve better in vitro
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potency/in vivo efficacy for chemoprevention or anticancer effects [85]. To modulate ITC
in hybrid drugs, we designed two Enz-ITC hybrids with four-carbon (compound 12a) and
six-carbon chain (compound 12b), respectively (Figure 9). Since we hypothesized that
the cellular effects of ITC could be locally directed to Hsp90-AR complex by an AR
ligand, compound 19 which is a close structural analogue of 12b (C6-ITC) was designed
to investigate the directing effect of AR. The cyano (CN) group, which forms H-bond
with AR, was converted to t-Butyl amide to eliminate AR binding property from
compound 12b. It worth to mention that 19 and 12b have similar LogP values (6.37 and
6.39, respectively), suggesting similar lipophilicity and potentially close intracellular
accumulation of these two compounds. If AR affinity plays a role in the cellular effect of
12b (C6-ITC), 12b should be more effectively disrupt Hsp90 and causes AR degradation
at a lower concentration compared to 19 and SFN. The comparison of 12b with a
synthetic intermediate 11b (C6-N3) will also be made using kb2-cell-based ARE
luciferase assay. 12b and 11b has identical chemical structure except the ITC (N=C=S)
moiety in 12b and chemically inert azide group (N=N=N) in 11b. We envisioned that
11b is an ideal 12b analogue to study the AR antagonist activity of the chemical scaffold
shared by 12b and 11b. Compound 11b is expected to display Enz-comparable AR
antagonist activity in ARE-luciferase assay.
The N-acetyl cysteine (NAC) conjugates are the ultimate metabolites of many
dietary ITCs. It should be noted that ITC-NAC conjugates are still biologically active,
comparable to parental ITCs [86, 87]. NAC conjugates could be seen as a carrier of ITC
in systemic circulation. At least three mechanisms have been proposed to understand the
bio-effectiveness of ITC-NAC: 1) ITC-NAC and parental ITC forms equilibrium in
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biological matrix [88], the NAC conjugate acts as a pool to release ITC; 2) The NAC
conjugate directly acts as a HDAC inhibitor, in contrast to parental compound [72]; and 3)
ITC-NAC directly modify protein thiols via transthiocarbamoylation reaction [81].
Based on these reported mechanisms, we also designed and synthesized compound 13,
the NAC conjugate of 12. In our opinion, there are at least three potential advantages for
13: 1) increased water solubility; 2) direct HDAC inhibition; and 3) reduced plasma
protein binding in circulation which may improve in vivo efficacy.
As a moderate electrophile, the interactions between ITC and cancer cells are
complicated, multiple cellular targets could be hit. Although this might be a reason for

Figure 10. The chemical structures of proposed Enz-HDACi hybrid and its prodrug.
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ITCs (e.g., SFN) to display broad anticancer effects in various cancer types (including
PCa), the lack of specificity of ITC may lead to moderate potency and undesired side
effects if used at high dose range. In this thesis, we proposed to use an Enz-derived AR
ligand to localize ITC’s effects at AR-Hsp90-HDAC6 complex as way to improve the
potency and specificity of ITC. From this angle, another relevant but different strategy to
target AR-Hsp90-HDAC6 axis is to use a conventional HDACi pharmacophore instead
of ITC. The comparisons between the two classes of compounds, Enz-ITC vs. EnzHDACi on AR degradation, Hsp90 disruption and growth inhibition of PCa cells, will
enable the mechanistic dissection of the cellular actions of Enz-ITC series. To
preliminarily explore Enz-HDACi class, we designed compound 1005 and its carbamate
prodrug 1005pro (29) (Figure 10). A three-carbon cinnamyl linker was used to link the
Enz moiety with hydroxamic acid, a typical and potent zinc binding group for HDAC
inhibition. The cinnamyl linker is frequently used in the design of HDACis, as seen in
FDA-approved panobinstat and belinostat. Because hydroxamic acid is known to be
metabolic labile due to phase 2 conjugation and has poor permeability to penetrate solid
tumor [89], we also converted 1005 to a carbamate prodrug according to a published
procedure [90] with an intention to avoid these liabilities. The carbamate bond is
expected to be hydrolyzed by esterases inside the cell to release 1005. The interactions of
1005 with AR and HDAC6 are supported by our molecular docking results.
2.2.2. Biological Evaluation
To demonstrate AR directing hypothesis, we need to firstly investigate if the
hybrid scaffold keeps the AR affinity as well as AR antagonistic activity. We planned to
use dihydrotestosterone (DHT)-stimulated LNCaP cell growth inhibition and MDA-Kb2
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cell based ARE luciferase assays for this purpose. The growth of androgen-sensitive PCa
cell line, e.g. LNCaP, is stimulated by androgen such as DHT, and AR antagonist (e.g.,
Enz) would block such growth stimulation. If the Enz-ITC hydroxyl analogue 9 with no
ITC activity could reverse the stimulation, then the result would partially supports the AR
antagonist property of the hybrid. A more direct ARE-luciferase assay was utilized to
characterize the interactions of a small molecule ligand with AR. MDA-kb2 cell line, a
breast cancer MDA-MD-453 cell line derivative, expresses high levels of AR and is
permanently transfected with an androgen-responsive luciferase reporter plasmid. It
responses to androgen and produce luminescence after incubation with a luciferase
substrate [91]. By measuring the luciferase activity of drug-treated cells in the presence
of DHT, we could clearly know the influence of drug on the transcriptional activity of
AR. We intend to use ARE luciferase activity as a readout of the interactions between an
AR ligand and the receptor. A high-affinity AR antagonist is expected to more effectively
inhibit luciferase activity compared to a low-affinity antagonist.
By comparing with SFN and analogues without AR binding, we also investigated
if the proposed Enz-ITC hybrid could more effectively cause degradation of Hsp90
clients, such as AR and Akt in AR+ LNCaP cells. Western blot analysis was performed
to determine the change of protein levels for AR and Akt. In addition to Hsp90 clients,
because ITCs has been reported to be cellular HDACis [44], acetylated histone 3 (Ac-H3),
acetylated histone 4 (Ac-H4) and acetylated tubulin (Ac-Tub) which are markers
representing globe HDACi activity in nuclear and cytosol respectively, was examined via
western blot analysis and was correlated with the cellular protein levels of AR.
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Then overall anticancer effects of Enz-ITC hybrid were tested on both androgensensitive (LNCaP) and androgen-insensitive (22Rv1 and PC-3) PCa cell lines using MTT
assay and compared with those of SFN and Enz, the parental compounds. Among these
cell lines, LNCaP and 22Rv1, both express full length, mutated AR, while 22Rv1 also
express AR splice variants (e.g., AR-V7); androgen-insensitive PC-3 doesn’t express AR
[92].
In addition to PCa, Enz has the potential to be used for breast cancer treatment
[93]. As a starting point to test tolerability of Enz-ITCs in noncancerous cells, we chose a
noncancerous breast cancer cell line MCF-10A as cell culture model. Comparisons were
made between Enz-ITCs and SFN in MCF-10A cells using MTT assay.
2.2.3. Molecular Docking of Enz-ITC with AR
Molecular docking is an important methodology in modern drug discovery to
understand the interactions of a ligand with its protein target. We used molecular docking
to examine the AR binding of proposed hybrid.
AR belongs to the nuclear receptors superfamily and consists of five domains: Nterminal regulatory domain contains the activation function 1 (AF-1) which functions
independent of ligand biding. DNA-binding domain (DBD) binds to specific androgen
response elements (ARE) on DNA to transcript target genes upon hormone activation.
Ligand binding domain (LBD) is responsible for hormone binding, dimerization process
and includes a ligand dependent transcriptional activity (AF-2). Hinge region is a flexible
domain that connects the DBD with the LBD which includes a part of the nuclear
localization signal [94, 95]. Androgen binding activates AR and results in a
conformational change of the receptor which leads to dissociation of AR from cytosolic
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heat shock proteins, dimerization and translocation to nucleus. Then DBD interacts with
ARE as a homodimer to recruit transcription machinery and transcript AR-regulated
target genes [95]. Revealed by X-ray diffraction structures of several nuclear receptors
complexed with their antagonists, the receptor antagonism is caused by antagonistinduced displacement of helix 12 from its hormone-bound configuration and distortion of
coactivator binding site [84]. It has been suggested that nuclear receptor family shares
similar structure, function and mechanism, however, the conformation of antagonistic AR
has not been experimentally resolved. Due to the distinct conformational difference
between AR agonistic and antagonistic forms, traditional molecular modeling method
such as “flexible ligand-rigid protein” and “induced fit docking” are not suitable for the
study of the interactions of AR with a given antagonist. Although molecular dynamic
(MD) simulation is theoretically competent, dramatic AR conformational transformation
between agonistic and antagonistic forms make the simulation extremely time and
computational power consuming.
Homology modeling is a method that could achieve a balance between
computational power and precise result [96]. Homology modeling technique constructs
an atomic-resolution model of target protein with known amino acid sequence based on
the three-dimensional structure of homologous protein (template). This method is based
on the observation that proteins with similar sequences usually possess similar 3D
structures because protein tertiary structure is better conserved than amino acid sequence.
Wilkinson’s

study

[97]

suggested

that

glucocorticoid

receptor

(GR)

and

mineralocorticoid receptor (MR) are more suitable 3D templates for AR. However, the
structure of MR in antagonist form is not currently available. Combining with the
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experience of Pepe’s group [96], we decided to use antagonistic GR structure (PDB code:
1NHZ) [98] ) as the template for homology modeling. The molecular docking was
performed by using Glide software (trial version).
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Chapter 3. Result and Discussion
3.1. Chemistry
3.1.1. Synthesis of Enz-ITC (Compound 13)
The synthesis of Enz-ITC hybrid is described in . Four- or six-carbon chain was
first introduced to pyridine ring through Sonogashira coupling to generate 3. To prevent
the potential interferences in following steps, the hydroxyl group of 3 was protected with
methoxymethyl acetal (MOM) protecting group. Then nitro group and alkyne were
reduced through catalytic hydrogenation to afford aromatic amine 5 which was alkylated
by 6 in the presence of sodium acetate in ethanol. Because of the low reactivity of the
aromatic amine, the alkylation reaction was refluxed for 10 days to achieve a reasonable
yield (73%). Several methods were reported for the synthesis of thiohydantoin ring [99101], here we used 21 which was prepared by mixing 20 with thiophosgene to react with
7 in DMSO at 80°C to generate the cyclization product 8 with good yield (90%). MOM
protecting group was removed by using hydrochloric acid, then the free hydroxyl group
was activated to form methanesulfonate 10. Azide moiety was then installed by
substitution of the highly active methanesulfonyl group with sodium azide to give 11.
The azide intermediate 11 was converted to ITC via a one-pot two-step procedure [102]:
triphenylphosphine (PPh3) reacted with the azide to generate phosphazide or
iminophosphorane intermediates which further reacted with carbon disulfide (in excess)
to afford Enz-ITC 12. Conjugation of 12b with NAC in the presence of sodium
bicarbonate afforded the NAC conjugate 13.
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Scheme 1. Synthesis of Enz-ITC hybrid

Purification of NAC conjugate 13 was not straightforward. Although the
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conjugation reaction was smooth and clean when NAC was used in excess, it was
difficult to separate 13 from remained NAC by using either column chromatography or
preparative TLC. Rf values of NAC and 13 are extremely close on the TLC plate with
about 80% overlaps. We could not get a clean NMR spectrum even after repetitive
purifications. Because of their differences in water solubility, we also dissolved crude 13
in ethyl acetate or DCM, tried to wash NAC away with water. The procedure was not
successful at the beginning: the water and organic phases couldn’t be separated during
work up despite using different organic phases and long hours of standing. This
inconvenience was a reflection that 13 might function as an emulsifier due to the
presence of both lipophilic AR ligand and hydrophilic NAC moieties in the same
molecule. To our delight, an unexpected separation was achieved after storage of the
washing mixture at -20°C overnight. The water phase containing NAC was frozen and
was removed by pouring organic phase to another flask to evaporate. 13 with desirable
purity was finally obtained for subsequent biological studies.
In order to study whether AR affinity plays a role in the biological effects of EnzITC, we proposed to prepare compound 19 as a critical control (Scheme 2). To
synthesize this molecule, cyano group of intermediate 8b need to be converted to tertButyl amide analogue 19 by tert-Butyl acetate in the presence of sulfuric acid. We
expected that the acidic condition would also simultaneously remove the acid-labile
MOM protecting group. Indeed, as shown in proton NMR spectrum, single peak of tertButyl group (δ 1.43, s, 9H, three methyl groups) emerged accompanied by the loss of
MOM peaks (δ 4.60, s, 2H; 3.34, s, 3H). However, it came to our attention that an extra
acetyl peak (3H) at 2.00ppm was observed in proton NMR, which made us suspect that
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Scheme 2. Synthesis of Enz-ITC amide analogue 19

the primary alcohol of expected 16 was acetylated by tert-Butyl acetate in an acidic
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reaction mixture. This speculation was further confirmed by 13C and high resolution MS
analysis and we designated the reaction product as acetate 15. Hydrolysis of 15 by
sulfuric acid in methanol resulted in the ‘true’ hydroxyl intermediate 16. By following the
same procedures as described for the synthesis of 13, 19 was made as a model compound

Scheme 3. Synthesis of Enz-HDACi hybrid
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with ITC group and reduced AR affinity.
3.1.2. Synthesis of Enz-HDACi
Synthetic strategy for Enz-HDACi hybrid 1005 and its prodrug 1005pro (29) was
similar to that of Enz-ITC hybrid as depicted in . We first did the alkylation reaction to
generate 23 followed by the iodination at the para site of aniline which enabled the
introduction of linker to construct HDACi. The cyclization reaction was performed as
described previously to give thiohydantoin intermediate 25. Then a three-carbon chain
was introduced through Heck reaction by reacting compound 25 with ethyl acrylate in the
presence of palladium(II) acetate and tri(o-tolyl)phosphine. Acidic hydrolysis of ester 26
using a mixture of aqueous hydrochloric acid (37% v/v) and acetonitrile afforded
carboxylic acid 27 which was coupled with tetrahydropyran (THP)-protected hydroxyl
amine to generate intermediate 28. Final compound 1005 was obtained by removing THP
using TFA in methanol. Enz-HDACi 1005 was further converted to carbamate prodrug
29 according to a published procedure by reacting 1005 with carbonyldiimidazole (CDI)
and isopropylamine [90].
3.2. Enz-ITC chemical scaffold inhibits dihydrotestosterone (DHT)stimulated LNCaP cell growth
To test our hypothesis, we first need to demonstrate that the synthesized Enzrelated chemical scaffolds retain AR binding/AR antagonist activity. One convenient way
for this purpose is to test whether a compound can block DHT-stimulated LNCaP cell
growth. DHT is a potent endogenous androgen and the growth of AR+ LNCaP cell is
sensitive to the stimulation of DHT [103]. Compound 9b (C6-OH) was chosen as a

33
representative Enz-ITC scaffold to exclude the potential interference of ITC on the
viability of cells. LNCaP cells were seeded in RPMI1640 medium supplemented with 10%
steroid-free charcoal-stripped serum. Measured by using MTT assay, DHT (1nM)
significantly stimulated cell growth (96h), and this enhanced growth was completely
inhibited by the treatment of C6-OH (10µM or 20µM) (Figure 11). Enz (10µM) was
used as the positive control. When cells were grown in charcoal-stripped media without
DHT, compared to DMSO control, Enz (10µM) or C6-OH (10µM, 20µM) neither

Figure 11. Enz-ITC chemical scaffold inhibied dihydrotestosterone (DHT)-stimulated
LNCaP cell growth. *** P < 0.0001
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stimulated cell growth nor reduced the viability of LNCaP cells. These results suggest
that C6-ITC scaffold is not cytotoxic, the drug-caused counteraction to DHT was due to
AR antagonist activity of the new chemical scaffold.
3.3. Enz-ITC scaffold inhibits AR transcriptional activity
Results from DHT growth stimulation assay could only indirectly demonstrate
AR antagonistic binding of C6-OH. To directly measure the influence of Enz-ITC
scaffold on AR transcriptional activity, we performed ARE luciferase assay in MDA-kb2
Cells. MDA-kb2 cell line was derived from the breast cancer cell line MDA-MD-453
which was stably transfected with an androgen-responsive luciferase reporter plasmid
driven by the mouse mammary tumor virus (MMTV) promoter. MDA-MD-453 and
MDA-kb2 cell lines express high levels of AR and the androgen responsive feature of
MMTV promoter has

been well characterized [91]. When DHT binds to AR, the

liganded AR can further activate the MMTV.neo.luc response element which leads to
induction of luciferase expression. Since AR antagonist competes with DHT for AR
binding, the activation of AR by DHT would be diminished in the presence of an
antagonist, which silences luciferase expression. After adding luciferase substrate,
fluorescence is generated and the intensity is proportional to the extent of DHT binding.
Within the same series of antagonist, since they have similar interaction mode with AR,
luciferase activity can be correlated with the binding affinity of AR: a high-affinity
antagonist can more effectively inhibit DHT-induced luciferase activity compared to a
low-affinity analogue.
In our experiment, DHT treatment (1nM) significantly increased luciferase
activity (Figure 12A). Enz, as the positive control, inhibited luciferase activity at all
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Figure 12. Enz-ITC scaffold antagonistically binds to AR (A). Treatment with
compounds alone do not reduce luciferase activity (B). *** P < 0.0002
concentrations (1-10µM). All the compounds with Enz-ITC scaffold decreased luciferase
activity in a dose-dependent fashion. 9b (C6-OH), although was not as good as Enz at
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Figure 13. Superposition of AR and GR in agonistic form. Two entities have very
similar 3-D structure.

1µM, it was comparable to Enz at higher concentrations (2.5-10µM). 9a (C4-OH) which
has a shorter linker was inferior to C6-OH, suggesting that the length of carbon chain
influences AR binding. However, two azide analogues C6-N3 and C4-N3 had almost
identical potency in this assay and were similar to that of C6-OH. C6-ITC (12b) and the
conjugate C6-ITC-NAC (13) has similar pattern as to that of C6-OH, less effective at
1µM but comparable to Enz at higher concentrations. Isothiocyanate derivatives, SFN
and PEITC-NAC which is a NAC conjugate of PEITC, didn’t decrease luciferase activity
due to lack of AR binding moiety. This also demonstrates that the reduced luciferase
activity is only related with Enz moiety at the tested concentration range ((1-10µM) and
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Figure 14. Superposition of GR in agonistic and antagonistic form. Two entities have
identical structure except for displaced helix 12 in antagonistic form.

time frame (24h). Amide analogues 14 didn’t have AR binding as we expected maybe
because of missing important H-bond interaction on cyano group. No luciferase activity
was either reduced or induced when treated with compounds alone at full range of
concentrations, (Figure 12B) indicating reduced luciferase activity came from the
inhibition of DHT binding to AR.
3.4. Molecular Docking of Enz-ITC to AR
Molecular docking studies were performed to better understand the interactions of
Enz-ITC with AR.
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Figure 15. Superposition of agonistic AR and homologous AR. Helix 12 in
homologous AR is pushed away from binding pocket to generate antagonistic form of
AR.
By examining the structures of AR and GR in antagonistic form, we found that
after superposition, the two entities have very similar 3-D structures (Figure 13) which
supports the use of GR as a suitable homology modeling template for AR. Besides,
agonistic and antagonistic form of GR had identical 3D structure except for helix 12
which is pushed away from binding pocket in the antagonist mode (Figure 14), this result
is consistent with the general antagonistic mechanism of nuclear receptor. When
superposing agonistic AR (complexed with DHT) (PDB code: 2AMB) [104] with AR in
antagonistic form obtained from homology modeling, two structures overlapped very
well and the displaced helix 12 of homologous AR created space to accommodate larger
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Figure 16. Surface of binding cavity of native ligand (DHT). Space in binding cavity
is closed and limited.

antagonist (Figure 15). And all these computational models built the foundation for
reliable docking studies.
The surface of binding cavity of agonistic AR with naive ligand (DHT) as
depicted in (Figure 16) indicates a closed and very limited space for ligand binding. Four
new pockets were identified in new homologous model (Figure 17 left), two opened
toward back of helix 11 (not shown in figure), one squeezed into the space between helix
11 and helix 12 and caused relaxation of helix 11 to form the pocket. Another pocket
opened toward the space where were originally occupied by helix 12 from agonistic
conformation (Figure 17 right).
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Figure 17. New binding pockets in homologous AR. Two open toward back of helix
11 (not shown in figure), one squeezes into the space between helix 11 and helix 12
(left). Another one opens toward the space (indicated by yellow circle) where were
originally occupied by helix 12 from agonistic conformation (right).
Docking results indicate C6-ITC had the similar binding mode and position to that
of Enz (Figure 18) in which cyano group on both C6-ITC and Enz formed two H-bond
with Gln711 and Arg752. This result emphasized the importance of cyano group in AR
binding of Enz scaffold and might explain why 14 lost its binding ability to AR. Besides,
Pi-Pi interactions were formed between Phe764 and benzonitrile rings on both C6-ITC
and Enz. Enz formed an extra H-bond with Phe876 through the hydrogen on amide group.
New pocket formed by relaxation of helix 11 provided the space for accommodation of
extended part of Enz as depicted in Figure 17. In conclusion, Enz-ITC scaffold kept the
antagonistic AR binding activity and potentially had the similar binding mode to that of
Enz.
3.5. Enz-ITC hybrid inhibits HDAC and causes downregulation of AR
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Figure 18. Docking of Enzalutamide and C6-ITC in homologous AR. Two molecules
have similar binding mode. Both form two H-bonds with AR (Gln711 and Arg752)
via cyano group and Pi-Pi interaction with Phe764. Enzalutamide forms extra H-bond
with Phe876.
We performed western blot analysis to investigate if the hybrid keeps the HDAC
inhibition and AR degradation activity of ITC. Acetyl-histone H3 (Ac-H3) and acetylhistone H4 (Ac-H4) are associated with HDAC activity in the nucleus, while acetyl-αtubulin (Ac-Tub) level is regulated by HDAC6 in the cytosol. Drug-induced HDAC
inhibition should cause increased globe acetylation of histones H3 and H4 and tubulin.
As shown in Figure 19., SAHA, as the positive control significantly increased acetylated
protein levels in a dose-dependent manner. C6-ITC also up-regulated Ac-H3 and Ac-tub
levels at 20µM, but had no effect on the level for Ac-H4. The C6-ITC-NAC showed
similar effects as C6-ITC but to a much lesser extent in protein acetylation. SFN also
increased Ac-tub level at 20µM but its nuclear effect was very weak.
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AR level was significantly down-regulated by C6-ITC even at 5µM, in contrast
SFN was not effective at this concentration. Although C6-ITC-NAC was inferior
compared to C6-ITC, it still outperformed SFN which only decreased AR level at high
concentration (20µM). AKT is an Hsp90 client protein and inhibition of Hsp90 leads to
degradation of Akt [105]. C6-ITC and C6-ITC-NAC decreased Akt level in a dosedependent fashion, suggesting that Enz-ITC hybrid disrupted the function of Hsp90. It is
worth to mention that PI3K/Akt pathway is up-regulated in CRPC and is involved in
many oncogenic processes. Previous study suggested that the AR and PI3K/AKT
pathways cross-regulate each other by reciprocal feedback which means inhibition of one
activates the other, thus maintaining tumor cell survival [26]. Recently, it was reported
that combination treatment with AZD5363 (an AKT inhibitor) and Enz significantly
delayed development of Enz resistance via synergistic increases of apoptosis and cell

Figure 19. Enz-ITC hybrid inhibits HDAC and causes downregulation of AR.
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cycle arrest [28]. Thus, effectively down-regulating both AR and Akt may indicate a
potential therapeutic advantage which needs to be further verified in other PCa models.
Whether C6-ITC-caused AR degradation is relevant to AR binding will be further studied
via the side by side comparison of C6-ITC and its analogue 19 which has just been
synthesized. Molecular docking study indicated that cysteine conjugate of C6-ITC has
similar binding mode with native ligand SAHA and can form four extra H-bond with
homologous HDAC6 (Figure 20), suggesting the possibility of HDAC6 inhibition
through forming ITC-Cys conjugate.
3.6. Enz-ITC inhibits proliferation in both androgen sensitive and insensitive
prostate cancer cell lines
We performed MTT assays to test overall antiproliferation activity of Enz-ITC

Figure 20. Binding mode of cysteine conjugate of C6-ITC with HDAC6.
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Table 1. In Vitro Inhibitory Activity (IC50).
IC50(μM)
Compd.

LNCaP

PC-3

22Rv1

C6-ITC

4.56 ±0.34

4.38 ±0.31

4.59 ±0.15

C4-ITC

8.27 ±0.78

7.34 ±0.36

8.18 ±1.12

C6-NAC

8.82 ±1.34

7.43 ±0.52

b

SFN

19.69 ±1.47

17.74 ±2.21

b

a

Values are the mean of a minimum of three experiments.

b

Not tested

hybrids. As indicated in Table 1, all Enz-ITC hybrids were more potent than SFN in all
the tested cell lines (LNCaP, 22Rv1 and PC-3) and C6-ITC (12b) was more active than
C4-ITC (12a). Although NAC conjugation reduced its antiproliferation activity, C6-NAC
(13) was still more effective than SFN. When cells were grown in full medium, as
expected, androgen insensitive cell lines PC-3 and 22Rv1 showed no response to Enz.
Because full growth media contains various steroid, such as estrogens that can also
stimulate LNCaP cells [106], Enz only showed weak growth inhibition effect to LNCaP
cell under this condition, e.g., Enz suppressed growth about 20% at 5μM (Figure 21).
Because no differences were seen between AR positive and AR negative cell lines (Table
1), the results from MTT assay seemed to be dominated by the “ITC” group. In order to
highlight the action of Enz moiety in hybrid, other AR positive, Enz-sensitive CRPC cell
lines, such as VCaP cells, need to be tested in future experiments.

Results from
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Figure 21. Comparation of combination treatment with Enz and SFN with Enz-ITC
hybird in different prostate cancer cell lines. * P < 0.05, ** P < 0.01, *** P < 0.005

combination treatment showed that Enz and ITC had no synergistic effect. Interestingly,
6-ITC treatment was superior than the combination at the same concentration in all the
three tested cell lines (Figure 21). Increased intracellular concentration might be partially
responsible for this “conjugation effects”, and whether AR binding also plays a role in
AR(+) cells, will be further investigated in VCaP cell through the comparison between
compound 13 (C6-ITC) and its analogue 19 which has reduced AR affinity.
3.7. Enz-ITC hybrids are more tolerable in MCF-10A cells than SFN
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Figure 22. Treatment of normal bresat cell (MCF-10A) and PCa cells (LNCaP, PC-3
and 22Rv1) with Enz-ITC hybrids and SFN.
Our previous experiments have demonstrated the effectiveness of Enz-ITC hybrid
in PCa cells. The effects on non-cancerous cells is another very important property of an
anti-cancer agent. Normal breast cell line MCF-10A was chosen to be tested considering
the promising potential of Enz and its analogues for breast cancer treatment. As shown in
Figure 22, at concentrations that induce effective AR down-regulation, C6-ITC (12b,
5µM) and C6-ITC-NAC (13, 10µM) showed certain selectivity between MCF-10A and
PCa cells. C6-ITC-NAC (13) was also more tolerable than SFN in MCF-10A cells.
3.8. Enz-HDACi inhibits proliferation in both androgen sensitive and
insensitive cell lines
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HDAC is one of the potential cellular targets of ITCs. To dissect the anti-PCa
mechanisms of Enz-ITCs, we synthesized Enz-HDACi to further evaluate if AR can
direct HDACi to Hsp90 complex.

1005 and its amide prodrug 29 (1005pro) were

synthesized and accessed in PCa cells by using MTT assay. The results (Figure 23)
indicate that 1005 has better inhibition activity than C6-ITC and is more potent in
androgen sensitive cell line, potentially due to AR directing effect. Prodrug 29 (1005pro)
retains the activity against PCa cells while slightly less effective than the parental drug.

Figure 23. Enz-HDACi inhibits proliferation in both androgen sensitive and
insensitive cell lines
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3.9. Summary and future direction
In this project, we’ve successfully synthesized two Enz-ITC hybrids and NAC
prodrug as well as a series of relevant analogues to illustrate the mechanism of bioactivity
and SAR. MTT and ARE-luciferase assays indicate that the chemical scaffold of EnzITC retains AR antagonist activity. Enz-ITC hybrid induces AR down-regulation more
effectively than SFN potentially due to HDAC inhibition and/or Hsp90 disruption. In
addition, the hybrids inhibit proliferation of both androgen sensitive (LNCaP) and
insensitive cell lines (22Rv1, PC-3). No synergistic antitumor effect is observed in the
combination of Enz and SFN which is less effective than the hybrids determine by MTT
assays in the tested cell lines. Enz-ITC-NAC conjugate were more tolerable in MCF-10A
cells than SFN. We’ve also synthesized Enz-HDACi hybrid and its prodrug to make
comparison with Enz-ITC hybrids and our MTT results suggest that both compounds
have anti-proliferation activity against androgen sensitive and insensitive prostate cancer
cell lines.
To investigate if AR binding plays a role in hybrid drug-induced AR downregulation and growth suppression, Enz-ITC and Enz-HDACi will be compared with
their counterparts with reduced AR affinity, respectively. In addition, to understand
chemical reactivity of ITC hybrids, analysis of ITC conjugation with GSH and ITC-NAC
decomposition to release ITC will be performed by using HPLC. Since inhibition of both
prostate and breast cancer stem cells by SFN has been reported [60, 107], it is interesting
to test whether Enz-ITCs has similar effects against prostate and/or breast cancer stem
cells.
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Chapter 4. Experimental
4.1. Chemistry
All reagents and solvents were purchased from commercial suppliers and used
without further purification unless otherwise stated. All of the reported yields are for
isolated products and are not optimized. The reactions were monitored by thin layer
chromatography (TLC) on precoated silica gel UV254 plates (SORBTECH) and
visualized under UV light or after staining by dip into a solution of phosphomolybdic
acid or Potassium permanganate and then heating on a hot plate. All NMR spectra were
obtained using Varian INOVA 600 MHz NMR spectrometer. Chemical shifts are
expressed in ppm as a δ value, and singlet (s), doublet (d), triplet (t), quartet (q), multiplet
(m) and broad singlet (br s) are used as abbreviations.
4-(5-Nitropyridin-2-yl)but-3-yn-1-ol (3a). In argon atmosphere, to a mixure of
2-bromo-5-nitropyridine (10.0g, 50mmol) and 3-butyn-1-ol (4.55g, 65mmol) in
acetonitrile were added copper iodine (190mg, 1mmol), bis(triphenylphosphine)
palladium(II) chloride (175mg, 0.25mmol) and TEA(34mL, 250mmol) slowly. The
reaction was stirred at room temperature overnight. Solvent was removed under reduced
pressure. The crude product was purified by flash chromatography (Hex/EA: 1:1) to
afforded brown oil (8.34g, 87%). 1H NMR (600 MHz, CDCl3) δ 9.33 (d, J = 3.0 Hz, 1H),
8.42 (dd, J = 8.4 and 2.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 3.88 (m, 2H), 2.76 (t, J = 6
Hz, 2H).
6-(5-Nitropyridin-2-yl)hex-5-yn-1-ol (3b). In argon atmosphere, to a mixture of
2-bromo-5-nitropyridine (13.2g, 65mmol) and 5-hexyn-1-ol (4.9g, 50mmol) in
acetonitrile

(70mL)

were

added

copper(I)

iodide

(190mg,

1mmol),
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bis(triphenylphosphine) palladium(II) chloride (175mg, 0.25mmol) and TEA (34mL,
250mmol) slowly at 0°C. The reaction was stirred at room temperature for 3hrs. Solvent
was removed under reduced pressure, mixture was diluted with EtOAc, the organic phase
was washed with water and brine, dried over anhydrous sodium sulfate and concentrated.
The crude product was purified by flash chromatography (Hex:EA=2:1) to afford brown
oil (10.5g, 95%). 1H NMR (600 MHz, CDCl3) δ 9.34 (d, J = 2.4 Hz, 1H), 8.40 (dd, J =
8.4 and 3 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 3.70 (t, J = 12 Hz, 2H), 2.54 (t, J = 12 Hz,
2H), 1.77-1.72 (m, 4H). 13C NMR (150 MHz, CDCl3) δ 149.10, 145.27, 142.41, 131.26,
126.74, 97.12, 62.19, 31.79, 24.38, 19.36.
2-(4-(Methoxymethoxy)but-1-yn-1-yl)-5-nitropyridine

(4a).

In

argon

atmosphere, to a solution of 3a (8.34g, 43.4mmol) in THF(80mL) were added DIPEA
(18mL, 108.6mmol), then bromo(methoxy)methane (7.2mL, 90%, 78mmol) was added
slowly. Reaction was stirred at room temperature overnight. Precipitate was filtered, the
solvent was evaporated away under reduced pressure, mixture was diluted with EtOAc,
the organic phase wash by water and brine. The crude product was purified by flash
chromatography (Hex/EA: 6:1→4:1) to afford orange solid (6.3g, 61%). 1H NMR (600
MHz, CDCl3) δ 9.73 (s, 1H), 8.81 (s, 1H), 7.94 (s, 1H), 5.06 (s, 2H), 4.17 (d, J = 5.4Hz,
2H), 3.77 (s, 3H), 3.19 (d, J = 5.4 Hz, 2H).
2-(6-(Methoxymethoxy)hex-1-yn-1-yl)-5-nitropyridine

(4b).

In

argon

atmosphere, to a mixture of 3b (10.5g, 47.7mmol) in THF (80mL) were added DIPEA
(12.5mL, 75.7mmol), then bromo(methoxy)methane (10.5g, 90%, 78mmol) was added
dropwise at 0°C. Reaction was stirred at room temperature for 6hrs. Solvent was removed
under reduced pressure, mixture was diluted with EtOAc, the organic phase was washed
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with water and brine, dried over anhydrous sodium sulfate and concentrated. The crude
product was purified by flash chromatography (Hex:EA=4:1) to afford brown oil (10.69g,
85%). 1H NMR (600 Mhz, CDCl3) δ 9.34 (d, J = 2.4 Hz, 1H), 8.40 (dd, J = 8.4 and 2.4Hz,
1H), 7.51 (d, J = 8.4 Hz, 1H), 3.70 (t, J = 12 Hz, 2H), 2.54 (t, J = 12 Hz, 2H), 1.77-1.72
(m, 4H). 13C NMR (150 MHz, CDCl3) δ 149.10, 145.27, 142.41, 131.26, 126.74, 97.18,
80.04, 62.19, 31.79, 24.38, 19.36.
6-(4-(Methoxymethoxy)butyl)pyridin-3-amine (5a). To a solution of 4a (8.40g)
in methanol, palladium on carbon (200mg) was added. Reaction was stirred at
pressurized hydrogen atmosphere (60 psi) overnight. during that time reaction was filled
with Hydrogen several times. After the mixture was filtered, solvent was evaporated
away under reduced pressure to afforded brown oil (7.81g, 95%). 1H NMR (600 MHz,
CDCl3) δ 8.00 (s, 1H), 6.90 (m, 2H), 4.59 (s, 2H), 3.56 (br s, 2H), 3.52 (t, J = 6.6 Hz, 2H),
3.32 (s, 3H), 2.68 (t, J = 7.2 Hz, 2H), 1.70-1.76 (m, 2H), 1.59-1.64 (m, 2H).

13

C NMR

(150 MHz, CDCl3) δ 152.04, 140.11, 136.83, 122.61, 122.49, 96.35, 67.62, 55.09, 37.01,
29.34, 26.69.
6-(6-(Methoxymethoxy)hexyl)pyridin-3-amine (5b). To a solution of 4b
(10.68g, 40.4mmol) in methanol was added palladium on carbon (250mg). Reaction was
stirred under hydrogen atmosphere (60 psi) overnight. After the mixture was filtered,
solvent was removed under reduced pressure to afford brown oil (9.05g, 94%). 1H NMR
(600 MHz, CDCl3) δ 8.00 (m, 1H), 6.90 (m, 2H), 4.59 (s, 2H), 3.54 (br s, 2H), 3.48 (t, J =
6.6 Hz, 2H), 3.33 (s, 3H), 2.65 (t, J = 15.6 Hz, 2H), 1.68-1.63 (m, 2H), 1.59-1.55 (m, 2H),
1.40-1.32 (m, 4H).

13

C NMR (150 MHz, CDCl3) δ 152.46, 140.00, 136.77, 122.57,

122.54, 96.35, 67.79, 55.07, 37.26, 30.10. 29.64, 29.09, 26.07.
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Methyl

2-((6-(4-(methoxymethoxy)butyl)pyridin-3-yl)amino)-2-

methylpropanoate (7a). To a solution of 5a (7.81g, 37.2mmol) and 6 (33.7g, 186mmol)
in ethanol was added sodium acetate (30.5g, 372mmol). Reaction was refluxed for 5 days.
Reaction was filtered, the solvent was evaporated away under reduced pressure. Mixture
was diluted with EtOAc, the organic phase washed by water and brine. Product was
purified by flash chromatography (Hex/EA: 1:2→EA) to afforded red oil (3.78g, 34.3%).
1

H NMR (600 MHz, CDCl3) δ 7.94 (d, J = 3 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.81 (dd,

J = 8.4 and 3 Hz, 1H), 4.59 (s, 2H), 3.97 (br s, 1H), 3.70 (s, 3H), 3.52 (t, J = 6.6 Hz, 2H),
3.33 (s, 3H), 2.68 (t, J = 7.8 Hz, 2H), 1.70-1.78 (m, 2H), 1.59-1.66 (m, 2H), 1.53 (s, 6H).
13

C NMR (150 MHz, CDCl3) δ 176.16, 152.20, 139.31, 138.32, 123.06, 122.34, 96.36,

67.62, 57.70, 55.01, 52.56, 36.98, 29.38, 26.58, 26.12 (2C).
3-((4-(6-(Methoxymethoxy)hexyl)phenyl)amino)-3-methylbutan-2-one

(7b).

To a solution of 5b (3g, 12.6mmol) and 6 (22.8, 126mmol) in ethanol was added sodium
acetate (15g, 189mmol). Reaction was refluxed for 13 days. After the mixture was
filtered, solvent was evaporated away under reduced pressure. Mixture was diluted with
EtOAc, the organic phase was washed with water and brine, dried over anhydrous
sodium sulfate and concentrated. The crude product was purified by flash
chromatography (Hex:EA=1:2) to afford yellow oil (3.1g, 73%). 1H NMR (600 MHz,
CDCl3) δ 7.90 (d, J = 3 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.78 (dd, J = 8.4 and 3 Hz, 1H),
4.56 (s, 2H), 4.00 (br s, 1H), 3.67 (s, 3H), 3.60 (t, J = 6.6 Hz, 2H), 3.48 (t, J = 6.6 Hz,
2H), 3.30 (s, 3H), 2.62 (t, J = 8.1 Hz, 2H), 1.66-1.60 (m, 2H), 1.58-1.52 (m, 2H), 1.50 (s,
6H), 1.38-1.29 (m, 4H). 13C NMR (150 MHz, CDCl3) δ 176.17, 152.53, 139.25, 138.21,
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123.09, 122.27, 96.31, 67.76, 57.67, 55.03, 52.51, 37.18, 29.96. 29.61, 29.11, 26.09 (2C),
26.04.
4-(3-(6-(4-(Methoxymethoxy)butyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (8a). In argon atmosphere, to
a solution of 7a (3.78g, 12.8mmol) in DMSO (25mL), 21 (8.78g, 38.5mmol) was added.
Reaction was stirred at 80℃ overnight. The mixture was diluted with EtOAc, the organic
phase washed by water and brine, dried over anhydrous sodium sulfate and concentrated.
The crude product was purified by flash chromatography (Hex:EA=2:1→1:1) to afforded
brown oil (5.8g, 90%). 1H NMR (600 Mhz, CDCl3) δ 8.45 (d, J = 2.4 Hz, 1H), 7.96 (d, J
= 8.4 Hz, 1H), 7.94 (s, 1H), 7.82 (d, J = 7.8, 1H), 7.54 (dd, J = 8.4 and 2.4 Hz, 1H), 7.33
(d, J = 8.4 Hz, 1H), 4.60 (s, 2H), 3.56 (t, J = 6.0Hz, 2H), 3.34 (s, 3H), 2.90 (t, J = 8.4Hz,
2H), 1.84-1.90 (m, 2H), 1.66-1.72 (m, 2H), 1.58 (s, 6H). 13C NMR (150 MHz, CDCl3) δ
180.32, 174.67, 163.64, 149.58, 137.44, 136.95, 135.26, 133.56 (q, J = 33.2 Hz), 132.16,
129.60, 127.04 (q, J = 4.7 Hz), 123.42, 121.82 (q, J = 273 Hz), 114.76, 110.24, 96.43,
67.43, 66.35, 55.16, 37.82, 29.44, 26.12, 23.71 (2C).
4-(3-(6-(6-(Methoxymethoxy)hexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (8b). In argon atmosphere, to
a solution of 7b (3g, 8.86mmol) in DMSO (15mL) was added 21 (6g, 26.3mmol).
Reaction was stirred at 80℃ overnight. The mixture was diluted with EtOAc, the organic
phase was washed with water and brine, dried over anhydrous sodium sulfate and
concentrated.

The

crude

product

was

purified

by

flash

chromatography

(Hex:EA=1:1→1:2) to afford yellow oil (4.2g, 90%). 1H NMR (600 Mhz, CDCl3) δ 8.46
(d, J = 2.4 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.83 (dd, J = 8.4
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and 1.8Hz, 1H), 7.54 (dd, J = 8.4 and 2.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 4.60 (s, 2H),
3.51 (t, J = 6.3Hz, 2H), 3.34 (s, 3H), 2.87 (t, J = 8.1Hz, 2H), 1.83-1.73 (m, 2H), 1.651.56 (m, 2H), 1.59 (s, 6H), 1.46-1.40 (m, 4H).

13

C NMR (150 MHz, CDCl3) δ 180.33,

174.69, 164.01, 149.52, 137.42, 136.93, 135.25, 133.61 (q, J = 33.2 Hz), 132.14, 129.50,
127.04 (q, J = 4.7 Hz), 123.38, 121.82 (q, J = 273 Hz), 114.74, 110.30, 96.39, 67.71,
66.35, 55.10, 38.10, 29.60, 29.47, 29.22, 26.05, 23.73 (2C).
4-(3-(6-(4-Hydroxybutyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (9a). To the solution of 8a
(5.8g, 11.4mmol) in methanol, Hydrogen Chloride (4N, in 1,4-dioxane) (15mL, 60mmol)
was added dropwise. Reaction was stirred at room temperature overnight. Mixture was
neutralized by saturated sodium bicarbonate, extracted with EA and washed by water and
brine, dried over anhydrous sodium sulfate and concentrated. The crude product was
purified by flash chromatography (Hex:EA=1:2 → 1:4 → EA) to afforded brown oil
(4.95g, 94%). 1H NMR (600 MHz, CDCl3) δ 8.40 (d, J = 2.4 Hz, 1H), 7.93 (d, J = 8.4 Hz,
1H), 7.92 (s, 1H), 7.80 (d, J = 8.4, 1H), 7.53 (dd, J = 8.4 and 2.4 Hz, 1H), 7.31 (d, J = 8.4
Hz, 1H), 3.63 (t, J = 6.6 Hz, 2H), 2.99 (br s, 1H), 2.86 (t, J = 7.8 Hz, 2H), 1.78-1.86 (m,
2H), 1.58-1.66 (m, 2H), 1.54 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 180.34, 174.67,
163.58, 149.43, 137.65, 137.02, 135.31, 133.37 (q, J = 33.2 Hz), 132.27, 129.70, 127.06
(q, J = 4.7 Hz), 123.62, 121.85 (q, J = 273 Hz), 114.81, 110.07, 66.39, 62.02, 37.45,
32.16, 25.66, 23.62 (2C).
4-(3-(6-(6-Hydroxyhexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (9b). To a solution of 8b
(1.68g, 3.14mmol) in methanol (15mL) was added hydrogen chloride (4N, in 1,4-dioxane)
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(4mL) dropwise. Reaction was stirred at room temperature for 3hrs. Mixture was
neutralized by saturated sodium bicarbonate, extracted with EtOAc and washed by water
and brine, dried over anhydrous sodium sulfate and concentrated. The crude product was
purified by flash chromatography (Hex:EA=1:1→1:2) to afford yellow foam (1.4g, 91%).
1

H NMR (600 MHz, CDCl3) δ 8.42 (d, J = 2.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.93 (d,

J = 1.2 Hz, 1H), 7.81 (dd, J = 8.4 and 1.2Hz, 1H), 7.53 (dd, J = 8.4 and 2.4 Hz, 1H), 7.31
(d, J = 8.4 Hz, 1H), 3.58 (t, J = 6.6 Hz, 2H), 2.84 (t, J = 7.8 Hz, 2H), 2.16 (br s, 1H),
1.80-1.72 (m, 2H), 1.56 (s, 6H), 1.58-1.50 (m, 2H), 1.44-1.36 (m, 4H);

13

C NMR (150

MHz, CDCl3) δ 180.35, 174.71, 163.92, 149.40, 137.62, 136.96, 135.29, 133.53 (q, J =
33.2 Hz), 132.19, 129.60, 127.052 (q, J = 4.7 Hz), 123.52, 121.81 (q, J = 273 Hz), 114.75,
110.18, 66.38, 62.50, 37.88, 32.43, 29.44, 29.00, 25.42, 23.66 (2C). HR-ESI-MS m/z
Calcd for C24H25F3N4O2S [M+H]+ 491.1729, found 491.1724.
6-(5-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)pyridin-2-yl)hexyl

methanesulfonate

(10b).

In

argon

atmosphere, to a stirred solution of 7 (1.35g, 2.75mmol) and triethylamine (1.15mL,
8.25mmol) in dichloromethane (15mL) was added methanesulfonyl chloride (0,42mL,
5.47mmol) at 0°C dropwise. Reaction was stirred at room temperature for 30min. Solvent
was removed under reduced pressure. The crude product was purified by flash
chromatography (Hex:EA=1:1→1:2) to afford white foam (1.47g, 94%).
4-(3-(6-(4-Azidobutyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin1-yl)-2-(trifluoromethyl)benzonitrile (11a). In argon atmosphere, to a stirred solution of
9a (820mg, 1.77mmol) in DCM and triethylamine (1.23mL, 8.87mmol) was added
Methanesulfonyl Chloride (0.55mL, 7.1mmol) dropwise at 0°C. Reaction was stirred at
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0°C for 30min and warm to room temperature for 1h. Mixture was washed by water and
brine, the solvent was evaporated away under reduced pressure. Mixture was redissolved
in DMF(15mL), sodium azide (345mg, 5.3mmol) was added. Reaction was stirred at
room temperature overnight. Mixture was diluted with EA, washed by water and brine.
The crude product was purified by flash chromatography (Hex:EA=1:2) to afforded
transparent oil (194mg, 25%). 1H NMR (600 Mhz, CDCl3) δ 8.48 (d, J = 1.8 Hz, 1H),
7.98 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.83 (d, J = 7.8Hz, 1H), 7.57 (dd, J = 8.4 and 2.4
Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 3.44 (t, J = 7.2 Hz, 2H), 2.91 (t, J = 7.8 Hz, 2H), 1.861.92 (m, 2H), 1.68-1.74 (m, 2H), 1.59 (s, 6H);

13

C NMR (150 MHz, CDCl3) δ 180.35,

174.65, 163.10, 149.67, 137.60, 136.89, 135.26, 133.65 (q, J = 33.3 Hz), 132.12, 129.78,
127.03 (q, J = 4.7 Hz), 123.47, 121.81 (q, J = 273 Hz), 114.72, 110.34, 66.35, 51.19,
37.43, 28.52, 26.47, 23.75 (2C). HR-ESI-MS m/z Calcd for C22H20F3N7OS [M+H]+
488.1491, found 488.1497
4-(3-(6-(6-Azidohexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin1-yl)-2-(trifluoromethyl)benzonitrile (11b). To a solution of 7 (1.47g, 2.59mmol) in
dimethylformamide (12mL) was added sodium azide (506mg, 7.8mmol). Reaction was
stirred at room temperature for 6hrs. Mixture was diluted with EtOAc, the organic phase
was washed with water and brine, dried over anhydrous sodium sulfate and concentrated
to afford yellow oil (1.5g). 1H NMR (600 Mhz, CDCl3) δ 8.45 (d, J = 2.4 Hz, 1H), 7.95
(d, J = 11.4 Hz, 1H), 7.95 (s, 1H), 7.82 (dd, J = 8.4 and 1.8Hz, 1H), 7.54 (dd, J = 8.4 and
2.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 3.24 (t, J = 7.2 Hz, 2H), 2.85 (t, J = 7.8 Hz, 2H),
1.81-1.73 (m, 2H), 1.62-1.55 (m, 2H), 1.57 (s, 6H), 1.45-1.38 (m, 4H);

13

C NMR (150

MHz, CDCl3) δ 180.33, 174.67, 163.77, 149.55, 137.46, 136.99, 135.26, 133.50 (q, J =
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33.3 Hz), 132.19, 129.57, 127.05 (q, J = 4.7 Hz), 123.41, 121.84 (q, J = 273 Hz), 114.77,
110.20, 66.36, 51.35, 37.97, 29.28, 28.87, 28.67, 26.49, 23.68 (2C). HR-ESI-MS m/z
Calcd for C24H24F3N7OS [M+H]+ 516.1785, found 516.1807
4-(3-(6-(4-Isothiocyanatobutyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (12a). To a solution of 11a
(194mg, 0.40mmol) in THF (5mL) was added triphenylphosphine (225mg, 0.86mmol).
Reaction was refluxed overnight. Then 3mL carbon disulfide was added, refluxed
overnight. Solvent was removed under reduced pressure. Mixture was washed by water
and brine. The crude product was purified by flash chromatography (Hex/EA: 1:1),
afforded transparent oil (53mg, 26%).1H NMR (600 MHz, CDCl3) δ 8.47 (d, J = 1.8 Hz,
1H), 7.97 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.57 (dd, J = 8.4 and
1.8 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 3.57 (t, J = 6.6 Hz, 2H), 2.90 (t, J = 7.8 Hz, 2H),
1.86-1.98 (m, 2H), 1.72-1.86 (m, 2H), 1.59 (s, 6H);

13

C NMR (150 MHz, CDCl3) δ

180.35, 174.64, 163.67, 149.73, 137.66, 136.94, 135.28, 133.56 (q, J = 33.2 Hz), 132.18,
129.88, 127.05 (q, J = 4.5 Hz), 123.52, 121.83 (q, J = 273 Hz), 114.77, 110.26, 66.38,
44.87, 37.03, 29.73, 29.52, 26.24, 23.74 (2C).
4-(3-(6-(6-Isothiocyanatohexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (12b). To a solution of 8
(1.5g 2.9mmol) in THF (10mL) was added triphenylphosphine (1.52g, 5.8mmol).
Reaction was refluxed overnight. Then carbon disulfide (9mL) was added, mixture was
refluxed for another 5hrs. Solvent was removed under reduced pressure. The crude
product was purified by flash chromatography (Hex:EA=1:1) to afford yellow
foam(905mg, 59%). 1H NMR (600 MHz, CDCl3) δ 8.45 (d, J = 2.4 Hz, 1H), 7.96 (d, J =
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9.0 Hz, 1H), 7.95 (s, 1H), 7.83 (dd, J = 8.4 and 1.8Hz, 1H), 7.55 (dd, J = 8.4 and 2.4 Hz,
1H), 7.32 (d, J = 8.4 Hz, 1H), 3.48 (t, J = 6.6 Hz, 2H), 2.86 (t, J = 7.8 Hz, 2H), 1.82-1.76
(m, 2H), 1.72-1.65 (m, 2H), 1.57 (s, 6H), 1.49-1.38 (m, 4H); 13C NMR (150 MHz, CDCl3)
δ 180.33, 174.67, 163.62, 149.57, 137.52, 136.99, 135.27, 133.49 (q, J = 33.2 Hz),
132.22, 129.62, 127.06 (q, J = 4.5 Hz), 123.47, 121.84 (q, J = 273 Hz), 114.77, 110.20,
66.37, 44.97, 37.87, 29.74, 29.16, 28.49, 26.33, 23.70 (2C). HR-ESI-MS m/z Calcd for
C25H24F3N5OS2 [M+H]+ 532.1453, found 532.1478.
N-acetyl-S-((6-(5-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo2-thioxoimidazolidin-1-yl)pyridin-2-yl)hexyl)carbamothioyl)-D-cysteine (13). To a
solution of 9 (300mg, 0.56mmol) in acetonitrile (3mL) was added N-acetyl-cysteine
(60mg, 0.37mmol) and Sodium bicarbonate (240mg, 2.86mmol). Reaction was stirred at
room temperature overnight. Then heated to 45°C overnight. Solvent was removed under
reduced pressure. The crude product was purified by flash chromatography (Hex:EA =
2:1 → 1:1 → DCM:MeOH:AcOH = 10:1:1%) . Purified product was washed by water to
get rid of remaining NAC and afford white foam (162.2mg, 63%). 1H NMR (600 MHz,
CDCl3) δ 8.64 (s, 1H), 8.54 (d, J = 1.8 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 1.2
Hz, 1H), 7.83 (dd, J = 8.4 and 1.8Hz, 1H), 7.67 (dd, J = 8.4 and 2.4 Hz, 1H), 7.40 (d, J =
8.4 Hz, 1H), 4.70 (q, J = 5.4 Hz, 1H), 3.78 (dd, J = 14.4 and 6.0 Hz, 2H), 3.70 (t, J = 6.6
Hz, 2H), 2.86 (t, J = 7.8, 2H), 1.99 (d, J = 7.8Hz, 3H), 1.82-1.71 (m, 2H), 1.71-1.63 (m,
2H), 1.59 (s, 6H), 1.50-1.36 (m, 4H);

13

C NMR (150 MHz, CDCl3) δ 196.52, 180.46,

174.58, 172.53, 171.71, 163.15, 148.45, 139.13, 136.94, 135.36, 133.53 (q, J = 33.2 Hz),
132.29, 130.35, 127.09 (q, J = 4.5 Hz), 124.31, 121.83 (q, J = 273 Hz), 114.77, 110.28,
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66.50, 53.71, 47.69, 36.83, 35.68, 29.36, 28.54, 27.67, 26.21, 23.75 (2C), 22.96. HR-ESIMS m/z Calcd for C30H33F3N6O4S3 [M+H]+ 695.1756, found 695.1743
4-(5-(3-(4-(Tert-butylcarbamoyl)-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4oxo-2-thioxoimidazolidin-1-yl)pyridin-2-yl)butyl acetate (14). To a solution of 9a
(108mg, 0.23mmol) in tert-butyl acetate (3mL) was added sulfuric acid (0.2mL) at 0°C.
Reaction was stirred at 42°C for 2hrs. Mixture was neutralized by saturated sodium
bicarbonate at 0°C, extracted with EtOAc and washed by water and brine, dried over
anhydrous sodium sulfate and concentrated. The crude product was purified by flash
chromatography (Hex:EA=1:1) to afford transparent oil (121mg, 91%). 1H NMR (600
MHz, CDCl3) δ 8.45 (s, 1H), 7.71 (s, 1H), 7.60 (m, 2H), 7.55 (dd, J = 8.4 and 2.4 Hz,
1H), 7.30 (d, J = 8.4 Hz, 1H), 5.77 (s, 1H), 4.07 (t, J = 6.6 Hz, 2H), 2.87 (t, J = 7.8 Hz,
2H), 2.00 (s, 3H), 1.87-1.80 (m, 2H), 1.75-1.68 (m, 2H), 1.54 (s, 6H), 1.41 (s, 9H); 13C
NMR (150 MHz, CDCl3) δ 181.29, 175.01, 171.15, 165.94, 163.00, 149.65, 137.68,
137.45, 133.88, 132.02, 129.99, 129.49, 127.93 (q, J = 32.6 Hz), 126.64(q, J = 5.3 Hz),
123.41, 123.06 (q, J = 273 Hz), 66.22, 64.12, 52.41, 37.53, 28.44 (3C), 28.35, 25.81,
23.66 (2C), 20.96.
6-(5-(3-(4-(Tert-butylcarbamoyl)-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4oxo-2-thioxoimidazolidin-1-yl)pyridin-2-yl)hexyl acetate (15). To a solution of 8b
(1.2g, 2.24mmol) in tert-butyl acetate (20mL) was added sulfuric acid (2mL) at 0°C.
Reaction was stirred at 42°C for 2hrs. Mixture was neutralized by saturated sodium
bicarbonate at 0°C, extracted with EtOAc and washed by water and brine, dried over
anhydrous sodium sulfate and concentrated. The crude product was purified by flash
chromatography (Hex:EA=2:1 → 1:1) to afford light yellow foam (810mg, 60%). 1H
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NMR (600 MHz, CDCl3) δ 8.45 (d, J = 1.8 Hz, 1H), 7.72 (s, 1H), 7.62 (m, 2H), 7.54 (dd,
J = 8.4 and 2.4 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 5.70 (s, 1H), 4.03 (t, J = 6.6 Hz, 2H),
2.84 (t, J = 7.8 Hz, 2H), 2.01 (s, 3H), 1.80-1.74 (m, 2H), 1.65-1.59 (m, 2H), 1.55 (s, 6H),
1.43 (s, 9H), 1.45-1.34 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 181.30, 175.03, 171.21,
165.92, 163.63, 149.62, 137.54, 137.45, 133.90, 132.03, 129.79, 129.51, 127.97 (q, J =
32.7 Hz), 126.65 (q, J = 4.5 Hz), 123.31, 123.06 (q, J = 273 Hz), 66.22, 64.44, 52.43,
38.02, 29.35, 29.00, 28.46 (3C), 28.43, 25.71, 23.69 (2C), 20.99. HR-ESI-MS m/z Calcd
for C30H37F3N4O4S [M+H]+ 607.2566, found 607.2263.
N-(tert-butyl)-4-(3-(6-(6-hydroxyhexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzamide (16). To a solution of 15
(415mg, 0.68mmol) in methanol (10mL) was added sulfuric acid (1mL). Reactio n was
stirred at 50°C for 1h. Mixture was neutralized by saturated sodium bicarbonate, diluted
with EtOAc and washed by water and brine, dried over anhydrous sodium sulfate and
concentrated to afford transparent oil (351mg, 91%). 1H NMR (600 MHz, CDCl3) δ 8.46
(d, J = 2.4 Hz, 1H), 7.73 (s, 1H), 7.64 (m, 2H), 7.55 (dd, J = 8.4 and 2.4 Hz, 1H), 7.31 (d,
J = 8.4 Hz, 1H), 5.67 (s, 1H), 3.62 (t, J = 6.6 Hz, 2H), 2.86 (t, J = 7.8 Hz, 2H), 1.82-1.75
(m, 2H), 1.62-1.53 (m, 2H), 1.57 (s, 6H), 1.44 (s, 9H), 1.47-1.37 (m, 4H); 13C NMR (150
MHz, CDCl3) δ 181.32, 175.07, 165.97, 163.73, 149.56, 137.59, 137.45, 133.92, 132.07,
129.77, 129.50, 127.95 (q, J = 32.6 Hz), 126.68 (q, J = 5.3 Hz), 123.38, 123.07 (q, J =
273 Hz), 66.25, 62.71, 37.97, 36.56, 32.52, 29.44, 29.05, 28.46 (3C), 25.45, 23.68 (2C).
HR-ESI-MS m/z Calcd for C28H35F3N4O3S [M+H]+ 565.2460, found 565.2466
6-(5-(3-(4-(Tert-butylcarbamoyl)-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4oxo-2-thioxoimidazolidin-1-yl)pyridin-2-yl)hexyl methanesulfonate (17). To a stirred
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solution of 16 (351mg, 0.62mmol) in dichloromethane (5mL) was added triethylamine
(0.7mL, 8.25mmol) and methanesulfonyl chloride (0.3mL, 5.47mmol). Reaction was
stirred at room temperature for 30min. Solvent was removed under reduced pressure. The
crude product was purified by flash chromatography (Hex:EA=1:1→1:2) to afford white
foam (360mg, 90%).
4-(3-(6-(6-Azidohexyl)pyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin1-yl)-N-(tert-butyl)-2-(trifluoromethyl)benzamide (18). To a solution of 17 (360mg,
56mmol) in dimethylformamide (5mL) was added sodium azide (182mg, 2.8mmol).
Reaction was stirred at 50°C overnight. Mixture was diluted with EtOAc, the organic
phase was washed with water and brine, dried over anhydrous sodium sulfate and
concentrated to afford yellow oil (359mg). 1H NMR (600 MHz, CDCl3) δ 8.46 (d, J = 2.4
Hz, 1H), 7.73 (s, 1H), 7.63 (m, 2H), 7.55 (dd, J = 8.4 and 2.4 Hz, 1H), 7.31 (d, J = 8.4 Hz,
1H), 5.67 (s, 1H), 3.24 (t, J = 6.6 Hz, 2H), 2.85 (t, J = 7.8 Hz, 2H), 1.83-1.75 (m, 2H),
1.63-1.58 (m, 2H), 1.56 (s, 6H), 1.44 (s, 9H), 1.46-1.39 (m, 4H);

13

C NMR (150 MHz,

CDCl3) δ 181.31, 175.04, 165.93, 163.58, 149.63, 137.56, 137.46, 133.90, 132.05, 129.81,
129.53, 127.98 (q, J = 32.1 Hz), 126.66 (q, J = 5.3 Hz), 123.34, 123.06 (q, J = 273 Hz),
66.23, 52.45, 51.36, 37.99, 29.30, 28.90, 28.68, 28.47 (3C), 26.51, 23.70 (2C). HR-ESIMS m/z Calcd for C28H34F3N7O2S [M+H]+ 590.2525, found 590.2520.
N-(tert-butyl)-4-(3-(6-(6-isothiocyanatohexyl)pyridin-3-yl)-4,4-dimethyl-5oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzamide (19). To a solution of
18 (180mg, 0.31mmol) in THF (5mL) was added triphenylphosphine (400mg, 1.55mmol).
Reaction was refluxed for 1h. Then Carbon disulfide (1.7mL) was added, mixture was
refluxed for another 1h. Solvent was removed under reduced pressure. The crude product
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was purified by flash chromatography (Hex:EA=2:1→1:1) to afford transparent
oil(107mg, 57%). 1H NMR (600 MHz, CDCl3) δ 8.44 (d, J = 2.4 Hz, 1H), 7.71 (s, 1H),
7.61 (s, 2H), 7.54 (dd, J = 8.4 and 2.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 5.66 (s, 1H),
3.47 (t, J = 6.6 Hz, 2H), 2.84 (t, J = 7.8 Hz, 2H), 1.74-1.81 (m, 2H), 1.64-1.71 (m, 2H),
1.55 (s, 6H), 1.41 (s, 9H), 1.37-1.48 (m, 4H);

13

C NMR (150 MHz, CDCl3) δ 181.28,

175.03, 165.93, 163.41, 149.64, 149.64, 137.59, 137.42, 133.90, 132.05, 129.84, 129.48,
127.93 (q, J = 32.1 Hz), 126.66 (q, J = 5.3 Hz), 123.38, 123.06 (q, J = 272 Hz), 66.22,
52.42, 44.96, 37.87, 29.74, 29.16, 28.50, 28.46 (3C), 26.33, 23.69 (2C). HR-ESI-MS m/z
Calcd for C29H34F3N5O2S2 [M+H]+ 606.2184, found 606.2183.
Methyl 2-((3-fluorophenyl)amino)-2-methylpropanoate (23). To a mixture of
3-flouroaniline (22)(10g, 90mmol) and methyl α-bromoisobutyrate (6)(27g, 14.9mmol) in
ethanol (70mL) was added sodium acetate (14.8g, 180mmol). Reaction was refluxed
overnight. Mixture was filtered, solvent was evaporated under reduced pressure. Mixture
was diluted with EtOAc, the organic phase was washed by water and brine, dried over
anhydrous sodium sulfate and concentrated. The crude product was purified by flash
chromatography (Hex:EA=15:1→10:1) to afford red oil (12.1g, 64%).

1

H NMR (600

MHz, CDCl3)  7.03-7.09 (m, 1H), 6.39-6.43 (m, 1H), 6.22-6.31 (m, 2H), 4.21 (br s, 1H),
3.71 (s, 3H), 1.56 (s, 6H).
Methyl 2-((3-fluoro-4-iodophenyl)amino)-2-methylpropanoate (24).

To a

mixture of 23 (4g, 19.0mmol) in H2O/dioxane (30mL/2mL) was added sodium
bicarbonate (6.37g, 75.8mmol) and iodine (5.8g, 22.7mmol). Reaction was stirred at
room temperature for 3h. Mixture was quenched by saturated sodium thiosulfate, and
extracted with EtOAc, washed by water and brine, dried over anhydrous sodium sulfate
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and concentrated. The crude product was purified by flash chromatography
(Hex:EA=10:1) to afford yellow solid (5.73g, 89%). 1H NMR (600 MHz, CDCl3) δ 7.30
(t, J = 8.4 Hz, 1H), 6.21(dd, J = 10.8 and 2.4 Hz, 1H), 6.06 (dd, J = 8.4 and 2.4Hz, 1H),
4.45 (br s, 1H), 3.63 (s, 3H), 1.47 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 175.95, 162.08
(d, J = 240.3 Hz), 147.76 (d, J=9.6Hz), 138.75 (d, J=2.3Hz), 112.66, 101.76 (d,
J=27.5Hz), 64.85 (d, J=25.8Hz), 57.22, 52.71, 25.93.
Ethyl (E)-3-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)-2-fluorophenyl)acrylate (26). In argon atmosphere, to a
mixture of 25 (4g, 7.9mmol), palladium(II) acetate (420mg, 1.88mmol) and tri(otolyl)phosphine (1.25g, 4.11mmol) in DMF/DIPEA (20mL/7mL) was added ethyl
acrylate (1.04mL, 9.76mmol). Reaction was stirred at 80°C overnight. Mixture was
diluted with EtOAc, the organic phase was washed by water and brine, dried over
anhydrous sodium sulfate and concentrated. The crude product was purified by flash
chromatography (Hex:EA=10:1) to afford brown solid (1.51g, 53%). 1H NMR (600MHz,
CDCl3):  7.96-7.99 (m, 2H), 7.79-7.85(m, 2H), 7.70(t, J=8.2Hz, 1H), 7.11-7.17 (m, 2H),
6.61(d, J=16.4Hz, 1H), 4.29(q, J=7.2Hz, 2H), 1.62(s, 6H), 1.36(t, J=7.2Hz, 3H).

13

C

NMR (150MHz, CDCl3): 179.74, 174.48, 166.28, 161.14 (d, J=255.5Hz), 137.36(d,
J=10.2Hz), 136.86, 135.51(d, J=1.0Hz), 135.24, 133.59(q, J=33.3Hz), 132.12, 129.98(d,
J=4.0Hz), 127.03(q, J=4.7Hz), 125.86(d, J=3.7Hz), 123.16, 122.85(d, J=6.5 Hz), 120.44,
117.91(d, J=23.6Hz), 114.68, 110.31(d, J=2.0Hz), 66.57, 60.88, 23.76, 14.21.
(E)-3-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)-2-fluorophenyl)acrylic acid (27). To a solution of 26 (1.51g,
2.99 mmol) in acetonitrile (35mL) was added HCl (37%, 25mL). Reaction was refluxed
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overnight. Mixture was diluted with EtOAc, the organic phase was washed by water and
brine, dried over anhydrous sodium sulfate and concentrated. The crude product was
purified by flash chromatography (Hex:EA:AcOH=2:1:0.5%) to afford orange solid
(1.31g, 92%). 1H NMR (600MHz, Acetone-d6)  8.28 (d, J = 8.0Hz,1H), 8.20 (d, J =
1.6Hz,1H), 8.08 (dd, J = 8.4Hz, 2.0Hz,1H), 8.01 (t, J = 8.4Hz, 1H), 7.83(d, J = 16Hz,
1H,), 7.37-7.42 (m, 2H), 6.71 (d, J = 16Hz, 1H), 1.68 (s, 6H).

13

C NMR (150MHz,

Acetone-d6)  181.38, 175.66, 167.21, 161.77 (d, J = 251.8Hz), 139.59 (d, J = 10.6Hz),
139.03, 136.66, 136.29 (d, J = 3.1Hz), 134.28, 132.89 (q, J = 32.7Hz), 130.69 (d, J =
3.9Hz), 128.50 (q, J = 4.9Hz), 127.52 (d, J = 3.5Hz), 124.66, 124.23 (d, J = 11.6Hz),
123.34 (d, J = 5.8Hz), 118.96 (d, J = 23.6Hz), 115.62, 110.29, 67.63, 23.65 (2C).
(E)-3-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)-2-fluorophenyl)-N-((tetrahydro-2H-pyran-2yl)oxy)acrylamide (28). In argon atmosphere, to a mixture of 27 (1.31mg, 2.75mmol),
NH2OTHP (0.35g, 3.1mmol) and BOP (1.34g, 3.1mmol) in DMF (15mL) was added
DIPEA (0.96mL, 5.50mmol). Reaction was stirred at room temperature overnight.
Mixture was diluted with EtOAc, the organic phase was washed by water and brine, dried
over anhydrous sodium sulfate and concentrated. The crude product was purified by flash
chromatography (DCM:EA=4:1) to afford white solid (730mg, 46%). 1H NMR (600MHz,
DMSO-d6): 11.42 (s, 1H), 8.37 (d, J=7.8Hz, 1H), 8.27(s, 1H), 8.05(d, J = 8.4Hz, 1H),
7.84(t, J = 7.8Hz, 1H), 7.56(d, J = 16Hz, 1H), 7.40 (d, J = 11Hz, 1H), 7.30 (d, J = 8.4Hz,
1H), 6.68 (d, J = 16Hz, 1H), 4.91 (s,1H), 3.94 (t, J = 8.4Hz, 1H), 3.52 (m, 1H), 1.65 (br s,
3H), 1.52 (br s, 9H).
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(E)-3-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)-2-fluorophenyl)-N-hydroxyacrylamide

(1005).

To

the

solution of 28 (672mg, 1.30mmol) in methanol (15mL) was added TFA (1.74mL,
22.7mmol). Reaction was stirred at 0°C for 6hrs. Mixture was diluted with EtOAc, the
organic phase was washed by water and brine, dried over anhydrous sodium sulfate and
concentrated. The crude product was purified by flash chromatography (Hex:EA=1:2) to
afford white solid (510mg, 89%). 1H NMR (600MHz, Methanol-d4)  8.15 (s, 1H), 8.13
(d, J = 8.4Hz, 1H), 7.97 (dd, J=8.4 and 1.2Hz, 1H), 7.74 (t, J=8.4Hz, 1H), 7.71 (d,
J=16.2Hz, 1H), 7.30 (dd, J = 10.8 and 1.8Hz, 1H), 7.26 (dd, J = 8.4 and 1.8Hz, 1H), 6.67
(d, J=16.2Hz, 1H), 1.57 (s, 6H).

C NMR (150MHz, Methanol-d4)  180.29, 175.08,

13

164.11, 160.90 (d, J=257.0Hz), 137.86, 135.95, 134.86, 133.89 (q, J=37.3Hz), 132.91,
130.90, 128.86 (q, J=4.8Hz), 127.70 (d, J=3.7Hz), 125.22 (d, J=11.7Hz), 125.01, 122.83,
122.30, 119.34 (d, J=23.8Hz), 114.55, 109.39, 66.62, 22.30 (2C). HR-ESI-MS m/z Calcd
for C22H17F4N4O3S [M+H]+ 493.0958, found 493.0960.
(E)-3-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2thioxoimidazolidin-1-yl)-2-fluorophenyl)-N-((isopropylcarbamoyl)oxy)acrylamide
(29). To a solution of 1005 (58mg, 0.12mmol) in acetonitrile (5mL) was added 1,1′Carbonyldiimidazole (29mg, 0.18mmol) at 0°C. Reaction was stirred at room
temperature for 2h. Then isopropylamine (21mg, 0.36mmol) was added and stirred for
another hour. Solvent was evaporated under reduced pressure. The crude product was
purified by Flash chromatography (Hex:EA=1:2→DCM:MeOH=20:1) to afford yellow
solid (32.7mg, 49%).1H NMR (600MHz, Methanol-d4)  8.16 (s, 1H), 8.15 (d, J = 8.4Hz,
1H), 7.98 (dd, J=8.4 and 1.8Hz, 1H), 7.82 (t, J = 8.4Hz, 1H), 7.79 (d, J=18.6Hz, 1H),
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7.33 (dd, J = 10.8 and 1.8Hz, 1H), 7.29 (dd, J = 7.8 and 1.8Hz, 1H), 6.75 (d, J=16.2Hz,
1H), 3.30 (m, 1H), 1.58 (s, 6H), 1.19 (d, J = 6.6Hz, 6H). 13C NMR (150MHz, Methanold4)  180.30, 175.08, 164.34, 161.03 (d, J=257.0Hz), 154.58, 137.92, 135.97, 134.86,
133.58 (q, J=37.3Hz), 132.91, 130.56, 128.45 (q, J=4.8Hz), 127.65 (d, J=3.7Hz), 125.10
(d, J=11.7Hz), 125.01, 122.83, 122.30, 119.34 (d, J=23.8Hz), 114.53, 109.42, 66.62,
43.60, 22.30 (2C), 21.27 (2C). HR-ESI-MS m/z Calcd for C26H23F4N5O4S [M+H]+
600.1305, found 600.1307.
4.2. Cell Cultures
LNCaP, PC-3, 22Rv1 cell lines were maintained in RPMI1640 supplemented with
10% FBS and 1% anti-biotic and grown at 37 °C in a humidified air with 5% CO2. MCF10A cell line were maintained in DMEM/F12 supplemented with 5% horse serum,
20ng/mL EGF, 0.5mg/mL hydrocortisone, 100ng/mL cholera toxin, 10µg/mL insulin, 1%
anti-biotic at 37 °C in a humidified air with 5% CO2.
4.3. MTT Assay
LNCaP, PC-3, and 22Rv1 cells (6 × 103 cells/well) were seeded into 96-well plate
overnight in RPMI 1640 containing 10% FBS and 1% anti-biotic (10A in DMEM/F12
supplemented with 5% horse serum, 20ng/mL EGF, 0.5mg/mL hydrocortisone,
100ng/mL cholera toxin, 10µg/mL insulin, 1% anti-biotic) and then incubated with
indicated concentrations of compounds for 72h or 96h. Then 20µl 5mg/mL MTT were
added to each well and incubated for 3.5h at 37 °C. Following the incubation, 100µl
DMSO was added and incubated for 30min at 37 °C. After that, Microplate reader
(BioTek) was used to measure absorbance of each well at 570 nm.
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For DHT growth stimulation assay, LNCaP cells (6 × 103 cells/well) were seeded
into 96-well plate overnight in RPMI supplemented with 10% charcoal stripped FBS and
1% anti-biotic and then incubated with indicated concentration of compounds with or
without 1nM DHT for 96h. The rest follow the procedure as described previously.
4.4. Luciferase Assay
MDA-kb2 cells were incubated in Leibovitz's L-15 supplemented with 10%
charcoal stripped FBS and 1% anti-biotic for 24h. Then MDA-kb2 (1 × 104 cells/well)
were seeded into opaque 96-well plate for 24h and incubated with indicated concentration
of compounds with or without 1nM DHT for 24h. For all procedure, cells were incubated
at CO2 free condition. After that, 125µl medium was removed and 75µl Steady-Glo®
reagent (Promega) was added.

Plate was shacked for 10min and microplate reader

(BioTek) was used to measure fluorescence.
4.5. Western Blotting
LNCaP cells (4 × 105 cells/well) were seeded into 6-well plate overnight in RPMI
1640 containing 10% FBS and 1% anti-biotic and then incubated with indicated
concentrations of compounds for 16h. The cells were detached and collected by
centrifugation at 14000rpm for 10min, then pellets were lysed with RIPA buffer
containing protease inhibitors and incubated on ice for 30 minutes. Protein concentrations
were determined by the Lowry assay. Protein were heated at 95°C for 5 minutes and
resolved by electrophoresis on SDS-PAGE and transferred to PVDF membrane. The
membrane was blocked by 5% milk for 1h, followed by incubation with primary antibody

68
overnight at 4°C. Then membrane was incubated with secondary antibody for 2h at room
temperature. Then membrane was visualized by ImageQuant™ LAS 4000 Imager (GE).
4.6. Homology Modeling and Molecular Docking
4.6.1 Androgen Receptor
Homology model for AR was constructed by using the antagonistic form of GR
structure (PDB code 1NHZ) as template [96]. The amino acid sequence of AR (PDB
code 2AMB) was aligned with that of 1NHZ. Homology model was built by using Prime
of Schrödinger followed by loop refinement, sidechain prediction, and minimization of
non-conserved residues. Molecular docking was performed by using Glide, during which
cyano group was set as constraint, all results were generated by XP model and flexible
docking, while the rest of setting were kept default. Docking poses were viewed and
displayed by Schrödinger Maestro.
4.6.2 HDAC6
Homology model for HDAC6 was constructed by using 1ZZ1 as template [108].
Amino acid sequence of human HDAC6 was aligned with that of 1ZZ1. Homology
model was built by using Prime of Schrödinger followed by loop refinement, sidechain
prediction, and minimization of non-conserved residues. Molecular docking was
performed by using Glide, during which zinc ion was set as constraint, all results were
generated by XP model and flexible docking, while the rest of setting were kept default.
Docking poses were viewed and displayed by Schrödinger Maestro.
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ABSTRACT
DESIGN AND SYNTHESIS OF ENZALUTAMIDE-ISOTHIOCYANATE
HYBRID DRUG AS ANTI-PROSTATE CANCER AGENT
by
SIYU OU
August 2016
Advisor: Dr. Zhihui Qin
Major: Pharmaceutical Sciences
Degree: Master of Science
Isothiocyanate (ITC), such as sulforaphane (SFN), is an active metabolite of
dietary glucosinolate from cruciferous vegetables. SFN-rich extracts have been recently
tested in recurrent prostate cancer (PCa) patients and notably prolonged PSA doubling
time without Grade 3 adverse events. One of the anti-PCa mechanisms of SFN is to inhibit
HDAC6, which further triggering androgen receptor (AR) degradation. We have
incorporated ITC to the chemical scaffold of enzalutamide (Enz) to create Enz-ITC hybrid
molecules with an intention to intracellularly deliver ITC to AR-Hsp90-HDAC6 complex
and therefore improving anti-PCa efficacy of both parental drugs. Two Enz-ITCs and one
Enz-ITC N-acetyl cysteine (NAC) conjugate, i.e. compound 12b (C6-ITC), 12a (C4-ITC)
and 13 (C6-NAC) were successfully synthesized. Our results support that Enz-ITCs
inhibit AR transcriptional activity, induce AR protein down-regulation (more effective
than SFN) and suppress proliferation of both androgen-sensitive and insensitive prostate
cancer cells. The AR antagonist activity of Enz-ITC was confirmed by the results of MTT
and ARE-luciferase assays. We’ve also synthesized amide analogue of Enz-ITC 19 with
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reduced AR affinity while keeps the activity of ITC for future mechanistic studies. As a
relevant strategy to study AR-directed HDAC inhibition, a representative Enz-HDAC
inhibitor (HDACi) hybrid, compound 1005 was synthesized. 1005 and its prodrug 29
suppressed proliferation of both androgen-sensitive and insensitive prostate cancer cells.
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